Search Results
Search for other papers by BA Reul in
Google Scholar
PubMed
Search for other papers by DJ Becker in
Google Scholar
PubMed
Search for other papers by LN Ongemba in
Google Scholar
PubMed
Search for other papers by CJ Bailey in
Google Scholar
PubMed
Search for other papers by JC Henquin in
Google Scholar
PubMed
Search for other papers by SM Brichard in
Google Scholar
PubMed
Molybdate (Mo) exerts insulinomimetic effects in vitro. In this study, we evaluated whether Mo can improve glucose homeostasis in genetically obese, insulin-resistant ob/ob mice. Oral administration of Mo (174 mg/kg molybdenum element) for 7 weeks did not affect body weight, but decreased the hyperglycaemia (approximately 20 mM) of obese mice to the levels of lean (L) (+/+) mice, and reduced the hyperinsulinaemia to one-sixth of pretreatment levels. Tolerance to oral glucose was improved: total glucose area was 30% lower in Mo-treated mice than in untreated ob/ob mice (O), while the total insulin area was halved. Hepatic glucokinase (GK) mRNA level and activity were unchanged in O mice compared with L mice, but the mRNA level and activity of L-type pyruvate kinase (L-PK) were increased in O mice by 3.5- and 1.7-fold respectively. Mo treatment increased GK mRNA levels and activity (by approximately 2.2-fold and 61% compared with O values), and had no, or only a mild, effect on the already increased L-PK variables. mRNA levels and activity of the gluconeogenic enzyme, phosphoenolpyruvate carboxykinase (PEPCK) were augmented in O liver (sixfold and by 57% respectively), and these were reduced by Mo treatment. Insulin binding to partially purified receptors from liver was reduced in O mice and restored by Mo treatment. Despite this correction, overall receptor tyrosine kinase activity was not improved in Mo mice. Moreover, the overexpression (by two- to fourfold) of the cytokine tumour necrosis factor alpha (TNF alpha) in white adipose tissue, which may have a determinant role in the insulin resistance of the O mice, was unaffected by Mo. Likewise, overexpression of the ob gene in white adipose tissue was unchanged by Mo. In conclusion, Mo markedly improved glucose homeostasis in the ob/ob mice by an insulin-like action which appeared to be exerted distal to the insulin receptor tyrosine kinase step. The blood glucose-lowering effect of Mo was unrelated to over-expression of the TNF alpha and ob genes in O mice, but resulted at least in part from attenuation of liver insulin resistance by the reversal of pre-translational regulatory defects in these mice.
Search for other papers by A Shirakami in
Google Scholar
PubMed
Search for other papers by T Toyonaga in
Google Scholar
PubMed
Search for other papers by K Tsuruzoe in
Google Scholar
PubMed
Search for other papers by T Shirotani in
Google Scholar
PubMed
Search for other papers by K Matsumoto in
Google Scholar
PubMed
Search for other papers by K Yoshizato in
Google Scholar
PubMed
Search for other papers by J Kawashima in
Google Scholar
PubMed
Search for other papers by Y Hirashima in
Google Scholar
PubMed
Search for other papers by N Miyamura in
Google Scholar
PubMed
Search for other papers by CR Kahn in
Google Scholar
PubMed
Search for other papers by E Araki in
Google Scholar
PubMed
Insulin receptor substrate 1 (IRS-1) gene polymorphisms have been identified in type 2 diabetic patients; however, it is unclear how such polymorphisms contribute to the development of diabetes. Here we introduced obesity in heterozygous IRS-1 knockout (IRS-1(+/-)) mice by gold-thioglucose (GTG) injection and studied the impact of reduced IRS-1 expression on obesity-linked insulin resistance. GTG injection resulted in approximately 30% weight gain in IRS-1(+/-) and wild type (WT) mice, compared with saline-injected controls. There was no difference in insulin sensitivity between lean IRS-1(+/-) and lean WT. Elevated fasting insulin levels but no change in fasting glucose were noted in obese IRS-1(+/-) and WT compared with the respective lean controls. Importantly, fasting insulin in obese IRS-1(+/-) was 1.5-fold higher (P<0.05) than in obese WT, and an insulin tolerance test showed a profound insulin resistance in obese IRS-1(+/-) compared with obese WT. The islets of obese IRS-1(+/-) were 1.4-fold larger than those of obese WT. The expression of insulin receptor and IRS-1 and IRS-2 was decreased in obese IRS-1(+/-), which could in part explain the profound insulin resistance in these mice. Our results suggest that IRS-1 is the suspected gene for type 2 diabetes and its polymorphisms could worsen insulin resistance in the presence of other additional factors, such as obesity.
Search for other papers by Zhang S-L in
Google Scholar
PubMed
Search for other papers by X Chen in
Google Scholar
PubMed
Search for other papers by TJ Hsieh in
Google Scholar
PubMed
Search for other papers by M Leclerc in
Google Scholar
PubMed
Search for other papers by N Henley in
Google Scholar
PubMed
Search for other papers by A Allidina in
Google Scholar
PubMed
Search for other papers by JP Halle in
Google Scholar
PubMed
Search for other papers by MG Brunette in
Google Scholar
PubMed
Search for other papers by JG Filep in
Google Scholar
PubMed
Search for other papers by SS Tang in
Google Scholar
PubMed
Search for other papers by Ingelfinger JR in
Google Scholar
PubMed
Search for other papers by JS Chan in
Google Scholar
PubMed
Clinical and animal studies have shown that treatment with angiotensin-converting enzyme (ACE) inhibitors or angiotensin II (Ang II) receptor antagonists slows the progression of nephropathy in diabetes, indicating that Ang II plays an important role in its development. We have reported previously that insulin inhibits the stimulatory effect of high glucose levels on angiotensinogen (ANG) gene expression in rat immortalized renal proximal tubular cells (IRPTCs) via the mitogen-activated protein kinase (p44/42 MAPK) signal transduction pathway. We hypothesize that the suppressive action of insulin on ANG gene expression might be attenuated in renal proximal tubular cells (RPTCs) of rats with established diabetes. Two groups of male adult Wistar rats were studied: controls and streptozotocin (STZ)-induced diabetic rats at 2, 4, 8 and 12 weeks post-STZ administration. Kidney proximal tubules were isolated and cultured in either normal glucose (i.e. 5 mM) or high glucose (i.e. 25 mM) medium to determine the inhibitory effect of insulin on ANG gene expression. Immunoreactive rat ANG (IR-rANG) in culture media and cellular ANG mRNA were measured by a specific radioimmunoassay and reverse transcription-polymerase chain reaction assay respectively. Activation of the p44/42 MAPK signal transduction pathway in rat RPTCs was evaluated by p44/42 MAPK phosphorylation employing a PhosphoPlus p44/42 MAPK antibody kit. Insulin (10(-7) M) inhibited the stimulatory effect of high glucose levels on IR-rANG secretion and ANG gene expression and increased p44/42 MAPK phosphorylation in normal rat RPTCs. In contrast, it failed to affect these parameters in diabetic rat RPTCs. In conclusion, our studies demonstrate that hyperglycaemia induces insulin resistance on ANG gene expression in diabetic rat RPTCs by altering the MAPK signal transduction pathway.
Search for other papers by CD McMahon in
Google Scholar
PubMed
Search for other papers by TH Elsasser in
Google Scholar
PubMed
Search for other papers by DR Gunter in
Google Scholar
PubMed
Search for other papers by LG Sanders in
Google Scholar
PubMed
Search for other papers by BP Steele in
Google Scholar
PubMed
Search for other papers by JL Sartin in
Google Scholar
PubMed
High doses of lipopolysaccharide (LPS) induce transient hyperglycemia, then chronic hypoglycemia and increased insulin resistance. In addition, appetite is reduced, while body temperature and concentrations of cortisol and tumor necrosis factor alpha (TNFalpha) are elevated. Furthermore, concentrations of GH and IGF-I are reduced in cattle. The objectives of this study were to determine whether a gonadal steroid implant (20 mg estrogen and 200 mg progesterone) given to endotoxemic steers would: (1) reduce hyperglycemia, reduce hypoglycemia, reduce insulin resistance, (2) reduce changes in concentrations of GH and IGF-I, (3) reduce inappetence and reduce concentrations of blood urea nitrogen (BUN) and non-esterified fatty acids (NEFA), and (4) reduce fever and concentrations of TNFalpha and cortisol. Holstein steers were assigned within a 2x2 factorial arrangement of treatments as follows (n=5 per group): C/C, no steroid and vehicle; S/C, steroid and vehicle; C/E, no steroid and LPS (1 microg/kg body weight (BW), i.v.); S/E, steroid and endotoxin. Steroid implants were given at 20 weeks of age (day 0) and serial blood samples (15 min) were collected on day 14 for 8 h, with vehicle or LPS injected after 2 h. Intravenous glucose tolerance tests (100 mg/kg BW) were carried out at 6 h and 24 h. Hyperglycemia was 67% lower (P<0.05) in S/E- compared with C/E-treated steers between 30 and 150 min after i.v. injection of LPS. Hypoglycemia developed after 4 h and insulin resistance was greater in S/E- compared with C/E-treated steers (P<0. 05) at 6 and 24 h. Concentrations of IGF-I were restored earlier in steroid-treated steers than in controls. Concentrations of GH were not affected by steroids, but increased 1 h after injection of LPS, then were reduced for 2 h. Appetite was greater (P<0.05) in S/E- (2.1% BW) compared with C/E-treated steers (1.1% BW) (pooled s.e.m.=0.3). Concentrations of NEFA increased after injecting LPS, but concentrations were lower (P<0.05) in S/E- compared with C/E-treated steers. LPS did not affect concentrations of BUN, but concentrations were lower in steroid-treated steers. Steroids did not affect body temperature or concentrations of TNFalpha and cortisol. In summary, gonadal steroids reduce hyperglycemia, reduce inappetence and tissue wasting, but increase insulin resistance. Furthermore, concentrations of IGF-I are restored earlier in steroid-treated than in non-steroid-treated steers injected with LPS. It is concluded that gonadal steroids reduce severity of some endocrine and metabolic parameters associated with endotoxemia. However, it is unlikely that gonadal steroids acted via anti-inflammatory and immunosuppressive actions of glucocorticoids or through reducing concentrations of cytokines.
Search for other papers by S. Matthaei in
Google Scholar
PubMed
Search for other papers by H. Benecke in
Google Scholar
PubMed
Search for other papers by H. H. Klein in
Google Scholar
PubMed
Search for other papers by A. Hamann in
Google Scholar
PubMed
Search for other papers by G. Kreymann in
Google Scholar
PubMed
Search for other papers by H. Greten in
Google Scholar
PubMed
ABSTRACT
To examine the cellular mechanism responsible for impaired insulin action in ageing, we determined various in-vitro parameters involved in the pathogenesis of insulin resistance, i.e. basal and insulin-stimulated [14C]3-O-methylglucose transport (30MG), 125I-labelled insulin binding, activation of insulin receptor kinase (IRKA) in intact cells, and number and subcellular distribution of glucose transporters in subcellular membrane fractions of adipocytes from 6- (FR-6) and 24- (FR-24) month-old Fischer rats. Ageing had no effect on basal 30MG (12±4 vs 13±3 fmol/5 × 104 cells, means ± s.e.m.); in contrast, in FR-24 rats insulin-stimulated 30MG was markedly decreased by 43% when compared with that in FR-6 rats (158±14 vs 90±8 fmol/5 × 104 cells; P < 0·01). Insulin binding to adipocytes from FR-6 rats was 2·40±0·38% compared with 2·28±0·47% in FR-24 (P not significant). Moreover, ageing had no significant effect on IRKA, as determined by insulin-stimulated (0, 1, 4 and 500 ng insulin/ml) 32P-incorporation into histone 2B. In subcellular membrane fractions, low density microsomes and plasma membranes, glucose transporter numbers were determined using [3H]cytochalasin B binding and immunodetection using an antiserum against the C-terminal peptide of the hepatoma-G2-glucose transporter. Cytochalasin B binding revealed that in the basal state the intracellular pool of glucose transporters was depleted in FR-24 by about 39% compared with low density microsomes from FR-6: (48·6±7·2 vs 29·8±5·5 pmol/mg membrane protein; P < 0·01). In consequence, in FR-24 there were fewer glucose transporters available for insulin-induced translocation to the plasma membrane (insulin-treated plasma membrane: 23·9±4·2 (FR-6) vs 14·4±3·1 (FR-24) pmol/mg membrane protein; P < 0·01). These results were confirmed by immunoblotting.
In conclusion, (1) maximal insulin-stimulated 30MG was decreased by 43% in cells from FR-24 rats compared with those from FR-6 rats, while basal 30MG was similar in both groups, (2) neither insulin binding nor IRKA were significantly altered in cells from FR-24 rats, and (3) impaired insulin-stimulated 30MG was associated with reduced numbers of glucose transporters in the plasma membrane as a consequence of a depletion of the intracellular pool of glucose transporters in cells from FR-24 rats.
Journal of Endocrinology (1990) 126, 99–107
Search for other papers by Márcio Pereira-da-Silva in
Google Scholar
PubMed
Search for other papers by Cláudio T De Souza in
Google Scholar
PubMed
Search for other papers by Alessandra L Gasparetti in
Google Scholar
PubMed
Search for other papers by Mário J A Saad in
Google Scholar
PubMed
Search for other papers by Lício A Velloso in
Google Scholar
PubMed
insulin resistance ( Ludwig et al. 2001 ). According to this study, these transgenic mice present a significantly higher blood glucose level during an intraperitoneal glucose tolerance test (ipGTT), which is accompanied by a markedly increased fed blood
Search for other papers by M Fasshauer in
Google Scholar
PubMed
Search for other papers by S Kralisch in
Google Scholar
PubMed
Search for other papers by M Klier in
Google Scholar
PubMed
Search for other papers by U Lossner in
Google Scholar
PubMed
Search for other papers by M Bluher in
Google Scholar
PubMed
Search for other papers by J Klein in
Google Scholar
PubMed
Search for other papers by R Paschke in
Google Scholar
PubMed
Various cytokines, including tumor necrosis factor (TNF) alpha, growth hormone (GH) and interleukin (IL)-6, induce insulin resistance. Recently, it was demonstrated that induction of suppressor of cytokine signaling (SOCS)-3 by TNFalpha and GH is an important mechanism by which these cytokines impair insulin sensitivity. The current study investigated in 3T3-L1 adipocytes whether TNFalpha and GH also upregulate SOCS-1 and SOCS-6, which have both been shown to inhibit insulin signaling potently, and whether IL-6 might alter synthesis of SOCS-1, -3 and -6. Interestingly, 10 ng/ml TNFalpha, 500 ng/ml GH and 30 ng/ml IL-6 induced SOCS-1 mRNA time-dependently with maximal stimulation detectable after 8 h of TNFalpha and 1 h of GH and IL-6 addition respectively. Furthermore, TNFalpha and GH caused sustained upregulation of SOCS-1 for up to 24 h, whereas stimulation by IL-6 was only transient, with SOCS-1 mRNA returning to basal levels 2 h after effector addition. Induction of SOCS-1 was dose-dependent, and significant stimulation was detectable at concentrations as low as 3 ng/ml TNFalpha, 50 ng/ml GH and 10 ng/ml IL-6. Furthermore, stimulation experiments and studies using pharmacologic inhibitors suggested that the positive effect of TNFalpha, GH and IL-6 on SOCS-1 mRNA is, at least in part, mediated by Janus kinase (Jak) 2. Finally, SOCS-3 expression was dose- and time-dependently induced by IL-6, at least in part via Jak2, but none of the cytokines affected SOCS-6 expression. Taken together, our results show a differential regulation of SOCS mRNA by insulin resistance-inducing hormones, and suggest that SOCS-1, as well as SOCS-3, may be an important intracellular mediator of insulin resistance in fat cells and a potential pharmacologic target for the treatment of impaired insulin sensitivity.
Search for other papers by A. H. Cincotta in
Google Scholar
PubMed
Search for other papers by J. M. Wilson in
Google Scholar
PubMed
Search for other papers by C. J. deSouza in
Google Scholar
PubMed
Search for other papers by A. H. Meier in
Google Scholar
PubMed
ABSTRACT
Naturally obese female Syrian hamsters were injected daily with prolactin at 0 or 12 h after cortisol injections for 10 days while held in constant light. Controls were similarly injected with saline. Animals were then held on short daylengths (10 h light:14 h darkness) for 10 weeks. They were allowed free access to food and water from birth to time of death. Ten weeks after treatment, retroperitoneal fat stores, plasma concentrations of insulin and glucose, and hypoglycaemic responsiveness to exogenous insulin were determined. The control groups as well as the 12-h hormone treatment group were obese, hyperinsulinaemic and insulin resistant. However, the 0-h treatment dramatically reduced retroperitoneal fat stores (41–55%), plasma insulin concentration (60–70%) and the insulin to glucose ratio (63–68%) compared with controls. Values for these parameters in the 0-h treatment groups were similar to those of their lean litter-mates. Furthermore, the 0-h group but not the 12-h group was more sensitive than control animals to the hypoglycaemic effects of exogenous insulin at doses 0·2 and 2·0 U/kg body weight. These results demonstrate that timed daily injections of cortisol and prolactin in specific temporal relationships can produce marked reductions in obesity, hyperinsulinaemia and insulin resistance in the Syrian hamster that persist long after the termination of treatment. This study also suggests an important role for the interactions of circadian neuroendocrine systems in the regulation of these metabolic states.
Journal of Endocrinology (1989) 120, 385–391
Search for other papers by Kechun Tang in
Google Scholar
PubMed
Search for other papers by Teresa Pasqua in
Google Scholar
PubMed
Search for other papers by Angshuman Biswas in
Google Scholar
PubMed
Search for other papers by Sumana Mahata in
Google Scholar
PubMed
Search for other papers by Jennifer Tang in
Google Scholar
PubMed
Search for other papers by Alisa Tang in
Google Scholar
PubMed
Search for other papers by Gautam K Bandyopadhyay in
Google Scholar
PubMed
David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, USA
Search for other papers by Amiya P Sinha-Hikim in
Google Scholar
PubMed
VA San Diego Healthcare System, San Diego, California, USA
Search for other papers by Nai-Wen Chi in
Google Scholar
PubMed
VA San Diego Healthcare System, San Diego, California, USA
Search for other papers by Nicholas J G Webster in
Google Scholar
PubMed
Search for other papers by Angelo Corti in
Google Scholar
PubMed
VA San Diego Healthcare System, San Diego, California, USA
Search for other papers by Sushil K Mahata in
Google Scholar
PubMed
membrane and calsequestrin in the lumen ( Boncompagni et al . 2012 ). We have previously shown hepatic insulin sensitivity but muscular insulin resistance in Chga -KO mice ( Gayen et al . 2009 ). Here, we show impaired muscle function, muscle fiber
Search for other papers by Sandra Pereira in
Google Scholar
PubMed
Search for other papers by Wen Qin Yu in
Google Scholar
PubMed
Department of Physiology, University of Toronto, Department of Medicine, Mount Sinai Hospital, Toronto General Research Institute and Banting and Best Diabetes Centre, University Health Network, Muscle Health Research Center and Physical Activity and Chronic Disease Unit, Faculty of Health, School of Kinesiology and Health Science, York University, Department of Internal Medicine, University of Manitoba, Medical Sciences Building, 1 King's College Circle, Toronto, Ontario, Canada M5S 1A8
Search for other papers by María E Frigolet in
Google Scholar
PubMed
Search for other papers by Jacqueline L Beaudry in
Google Scholar
PubMed
Search for other papers by Yaniv Shpilberg in
Google Scholar
PubMed
Search for other papers by Edward Park in
Google Scholar
PubMed
Search for other papers by Cristina Dirlea in
Google Scholar
PubMed
Search for other papers by B L Grégoire Nyomba in
Google Scholar
PubMed
Search for other papers by Michael C Riddell in
Google Scholar
PubMed
Department of Physiology, University of Toronto, Department of Medicine, Mount Sinai Hospital, Toronto General Research Institute and Banting and Best Diabetes Centre, University Health Network, Muscle Health Research Center and Physical Activity and Chronic Disease Unit, Faculty of Health, School of Kinesiology and Health Science, York University, Department of Internal Medicine, University of Manitoba, Medical Sciences Building, 1 King's College Circle, Toronto, Ontario, Canada M5S 1A8
Department of Physiology, University of Toronto, Department of Medicine, Mount Sinai Hospital, Toronto General Research Institute and Banting and Best Diabetes Centre, University Health Network, Muscle Health Research Center and Physical Activity and Chronic Disease Unit, Faculty of Health, School of Kinesiology and Health Science, York University, Department of Internal Medicine, University of Manitoba, Medical Sciences Building, 1 King's College Circle, Toronto, Ontario, Canada M5S 1A8
Search for other papers by I George Fantus in
Google Scholar
PubMed
Search for other papers by Adria Giacca in
Google Scholar
PubMed
Introduction Obesity leads to type 2 diabetes mellitus (T2DM) because of insulin resistance, and insulin resistance of obesity is due to elevated circulating levels of free fatty acids (FFAs) and cytokines ( Boden 1997 , Lewis et al . 2002
